The estimated Net Worth of Andrew Guggenhime is at least $12.4 Millón dollars as of 19 August 2024. Mr Guggenhime owns over 8,000 units of Vaxcyte stock worth over $11,890,956 and over the last 19 years he sold PCVX stock worth over $0. In addition, he makes $540,711 as Pres & CFO at Vaxcyte.
Mr has made over 42 trades of the Vaxcyte stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 8,000 units of PCVX stock worth $42,800 on 19 August 2024.
The largest trade he's ever made was exercising 36,000 units of Vaxcyte stock on 25 August 2022 worth over $192,600. On average, Mr trades about 5,718 units every 46 days since 2006. As of 19 August 2024 he still owns at least 104,720 units of Vaxcyte stock.
You can see the complete history of Mr Guggenhime stock trades at the bottom of the page.
Andrew L. Guggenhime M.B.A. is the Pres & CFO at Vaxcyte.
As the Pres & CFO of Vaxcyte, the total compensation of Mr A at Vaxcyte is $540,711. There are 3 executives at Vaxcyte getting paid more, with Grant E. Pickering M.B.A. having the highest compensation of $938,361.
Mr A is 53, he's been the Pres & CFO of Vaxcyte since . There are 2 older and 6 younger executives at Vaxcyte. The oldest executive at Vaxcyte, Inc. is Paul W. Sauer M.B.A., MBA, 60, who is the Sr. VP of Process Devel. & Manufacturing.
Andrew's mailing address filed with the SEC is C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA, 94070.
Over the last 12 years, insiders at Vaxcyte have traded over $60,439,674 worth of Vaxcyte stock and bought 1,293,000 units worth $20,688,000 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Capital Management, L.P.Ra ... y Llp Abingworth. On average, Vaxcyte executives and independent directors trade stock every 23 days with the average trade being worth of $2,563,959. The most recent stock trade was executed by Jim Wassil on 3 September 2024, trading 10,000 units of PCVX stock currently worth $24,200.
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Vaxcyte executives and other stock owners filed with the SEC include: